Actisal is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 6 years of age and older with reversible obstructive airway disease.
Levosalbutamol is a single isomer beta 2-agonist that differs from racemic salbutamol by elimination of (S)-salbutamol. Levosalbutamol is an effective bronchodilator whose primary mechanism of action is unimpeded by (S)-salbutamol. Thus, when compared with racemic salbutamol, clinically comparable bronchodilation can be achieved with doses that substantially lessen beta-mediated side effects.
Tablet- Adults and adolescents above 12 years: 1-2 mg three times daily. Children (6 -11 years): 1 mg three times daily. Syrup- Adults : 5-10 ml three times daily. Childrn (6-11 years): 5 ml three times daily.
Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea.
Levosalbutamol is contraindicated in patients with a history of hypersensitivity to levosalbutamol or any of its components.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Other short acting sympathomimetic bronchodilators or epinephrine should be used with caution with Actisal. If additional adrenergic drugs are to be administered by any route, they will be used with caution to avoid deleterious cardiovascular effects.
Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.